[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331817-105":59,"doc-detail-331817-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","xrcc1-a-potential-prognostic-and-immunological-biomarker-in-lgg-based-on-systematic-pan-cancer-analysis","XRCC1 - a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis","","X-ray repair cross-complementation group 1 (XRCC1) is a key component of base excision repair, yet its prognostic, immunological, and epigenetic roles across cancers remain insufficiently defined. A systematic bioinformatics analysis was performed across 33 cancer types using TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal data. Results assessed XRCC1 expression, prognosis/diagnosis, DNA methylation and phosphorylation, immune checkpoints, tumor mutation burden (TMB), microsatellite instability (MSI), immune and molecular subtypes, and immune infiltration. XRCC1 showed tumor-dependent associations with outcomes, links to epigenetic alterations, correlations with TMB/MSI, and significant relationships with immune checkpoint expression, suggesting XRCC1 as a pan-cancer prognostic and immunological biomarker and potential target for immunotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/xrcc1-a-potential-prognostic-and-immunological-biomarker-in-lgg-based-on-systematic-pan-cancer-analysis/331817/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/xrcc1-a-potential-prognostic-and-immunological-biomarker-in-lgg-based-on-systematic-pan-cancer-analysis/331817.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the XRCC1 pan-cancer analysis?","Question",{"text":112,"@type":113},"To evaluate XRCC1’s prognostic value, immunological functions, and epigenetic associations across 33 cancer types, addressing a lack of comprehensive pan-cancer evidence.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which datasets and bioinformatics resources were used in the study?",{"text":117,"@type":113},"The analysis leveraged data from TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal databases.",{"name":119,"@type":110,"acceptedAnswer":120},"How did XRCC1 relate to prognosis and immune features across tumors?",{"text":121,"@type":113},"XRCC1 correlations with prognosis were positive in some tumors and negative in others. XRCC1 also showed associations with immune checkpoint gene expression and immune infiltration patterns, including specific relationships with immune cell subsets.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331817,1790181795,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 1  \nResearch Paper  \nXRCC1: a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis  \nGuobing Wang1,2,*, Yunyue Li3,*, Rui Pan4,*, Xisheng Yin4, Congchao Jia4, Yuchen She4, Luling Huang5, Guanhu Yang6, Hao Chi4, Gang Tian1  \n1 Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China 2 Medical Clinical Laboratory, Yibin Hospital of T.C. M, Yibin, China  \n3Queen Mary College, Medical School of Nanchang University, Nanchang, China 4Clinical Medical College, Southwest Medical University, Luzhou, China  \n5 Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China 6 Department of Specialty Medicine, Ohio University, Athens, OH 45701, USA  \n*Equal contribution and share first authorship  \nCorrespondence to: Guanhu Yang, Hao Chi, Gang Tian; email: [guanhuyang@gmail.com](guanhuyang@gmail.com), [https://orcid.org/0000-0001-7888-](https://orcid.org/0000-0001-7888-)[ ](https://orcid.org/0000-0001-7888-)5759; [Chihao7511@163.com](Chihao7511@163.com), [https://orcid.org/0000-0002-5210-0770](https://orcid.org/0000-0002-5210-0770); [tiangang@swmu.edu.cn](tiangang@swmu.edu.cn)  \nKeywords: X-ray repair cross-complementation group 1, pan-cancer, prognosis, immune infiltration, tumor microenvironment  \nReceived: June 26, 2023 Accepted: December 1, 2023 Published: January 12, 2023  \nCopyright: © 2024 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nX-ray repair cross-complementation group 1 (XRCC1) is a pivotal contributor to base excision repair, and its dysregulation has been implicated in the oncogenicity of various human malignancies. However, a comprehensive pan-cancer analysis investigating the prognostic value, immunological functions, and epigenetic associations of XRCC1 remains lacking. To address this knowledge gap, we conducted a systematic investigation employing bioinformatics techniques across 33 cancer types. Our analysis encompassed XRCC1 expression levels, prognostic and diagnostic implications, epigenetic profiles, immune and molecular subtypes, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), immune checkpoints, and immune infiltration, leveraging data from TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal databases. Notably, XRCC1 displayed both positive and negative correlations with prognosis across different tumors. Epigenetic analysis revealed associations between XRCC1 expression and DNA methylation patterns in 10 cancer types, as well as enhanced phosphorylation. Furthermore, XRCC1 expression demonstrated associations with TMB and MSI in the majority of tumors. Interestingly, XRCC1 gene expression exhibited a negative correlation with immune cell infiltration levels, except for a positive correlation with M1 and M2 macrophages and monocytes in most cancers. Additionally, we observed significant correlations between XRCC1 and immune checkpoint gene expression levels. Lastly, our findings implicated XRCC1 in DNA replication and repair processes, shedding light on the precise mechanisms underlying its oncogenic effects. Overall, our study highlights the potential of XRCC1 as a prognostic and immunological pan-cancer biomarker, thereby offering a novel target for tumor immunotherapy.  \nINTRODUCTION  \nCancer represents a significant global public health challenge and is poised to surpass cardiovascular  \ndisease as the primary cause of non-natural mortality in many countries, based on prevailing year-to-year trends [1–8] . Recent reports indicate that in the year 2023, the United States is projected to witness 1,958,310 new  \ncancer cases, with an estimated 609,820 cancer-related deaths [9]. Among","cbCaialdIMqxDUeO","https://ap.wps.com/l/cbCaialdIMqxDUeO","pdf",7005904,39,"English","# Abstract\n## Study scope and data sources\n## Main analyses and biomarkers\n## Key findings and implications","[{\"question\":\"What was the main goal of the XRCC1 pan-cancer analysis?\",\"answer\":\"To evaluate XRCC1’s prognostic value, immunological functions, and epigenetic associations across 33 cancer types, addressing a lack of comprehensive pan-cancer evidence.\"},{\"question\":\"Which datasets and bioinformatics resources were used in the study?\",\"answer\":\"The analysis leveraged data from TCGA, GTEx, CELL, Human Protein Atlas, Ualcan, and cBioPortal databases.\"},{\"question\":\"How did XRCC1 relate to prognosis and immune features across tumors?\",\"answer\":\"XRCC1 correlations with prognosis were positive in some tumors and negative in others. XRCC1 also showed associations with immune checkpoint gene expression and immune infiltration patterns, including specific relationships with immune cell subsets.\"}]","XRCC1 - a potential prognostic and immunological biomarker in LGG based on systematic pan-cancer analysis | PDF",1789995315,98]